BRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy
May 2 ZIOPHARM Oncology Inc
* Ziopharm oncology announces fda acceptance of ind for cd33-specific car-t cell therapy targeting relapsed/refractory acute myeloid leukemia
* Ziopharm oncology inc - investigator-initiated ind application to fda for a phase 1 trial infusing cd33-specific car(+) t therapy is now active
* Ziopharm oncology inc - first patient to be enrolled in study expected to begin treatment in q3 of 2017. Source text for Eikon: Further company coverage:
UPDATE 1-South African parliament opposes calls to change central bank mandate
JOHANNESBURG, June 23 The South African parliament is planning to challenge in court an anti-graft watchdog's recommendation of constitutional changes to the mandate of the central bank, it said on Friday, highlighting worsening divisions between state institutions.